A Study of CS1002 in Subjects with Advanced Solid Tumors
A Phase Ia/Ib, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 As Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
Sponsor: CStone Pharmaceuticals
A PHASE1 clinical study on Solid Tumor, Adult, this trial is completed. The trial is conducted by CStone Pharmaceuticals and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Oct 2024 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1
▶ Show 7 earlier versions
-
Jan 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Aug 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2018 — Aug 2019 [monthly]
Recruiting PHASE1
-
Aug 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CStone Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .